Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELIRI and Avastin in 2nd Line Metastatic Colorectal Cancer
NCT00717990Phase 2Terminated
- Sponsor
- University Hospital of Crete
- Start
- Apr 2008
- Primary completion
- Dec 2012
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, bevacizumab, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in metastatic colorectal cancer (mCRC), sponsored by University Hospital of Crete. Started Apr 2008; status: terminated.
02
Drugs
capecitabinebevacizumabirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00717990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00717990.